Global Psoriatic Arthritis Therapeutics Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

• In March 2019, AbbVie Inc. announced that Japan's Ministry of Health, Labour and Welfare (MHLW) approved SKYRIZI (risankizumab), an interleukin-23 (IL-23) inhibitor, for treating plaque psoriasis, generalized pustular psoriasis, erythrodermic psoriasis, and psoriatic arthritis in adult patients with an inadequate response to conventional therapies.

• In October 2018, Novartis AG reported that the European Commission (EC) approved a label update for Cosentyx (secukinumab).

By drug class, the market includes various therapeutic options, such as nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), biologic agents, and targeted synthetic drugs. NSAIDs are often used as the first line of treatment to reduce pain and inflammation. DMARDs, which include methotrexate and leflunomide, help slow the progression of the disease and manage symptoms. Biologic agents, such as TNF inhibitors (e.g., infliximab, adalimumab) and IL-17 inhibitors, offer more targeted treatment for moderate to severe cases by targeting specific pathways involved in inflammation. Targeted synthetic drugs, including JAK inhibitors, represent the latest advancement in psoriatic arthritis therapeutics, offering oral treatment options that are gaining popularity for their efficacy and convenience.

The route of administration segmentation includes oral, subcutaneous, and intravenous methods. Oral administration is popular for convenience and patient compliance, especially with targeted synthetic drugs. Subcutaneous and intravenous routes are commonly used for biologics, providing rapid and efficient delivery directly into the bloodstream, often resulting in quicker relief of symptoms. The choice of administration route can impact patient preference, treatment adherence, and clinical outcomes, influencing the market landscape as providers and patients weigh the benefits of each method.

Distribution channels in the market include hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies play an essential role in dispensing therapeutics for patients receiving treatment within medical facilities, ensuring they have access to the specific drugs prescribed by their healthcare providers. Retail pharmacies provide convenient access for patients who need to fill prescriptions following outpatient consultations, contributing to the ongoing management of the condition. The growth of online pharmacies has further transformed the distribution landscape, offering patients the ability to order their medications online and receive home delivery, thereby improving accessibility and adherence to treatment plans.

Geography plays a significant role in the distribution and adoption of psoriatic arthritis therapeutics. North America and Europe are key markets, supported by advanced healthcare infrastructure, high awareness of autoimmune conditions, and widespread use of advanced therapeutics. The Asia-Pacific region is experiencing significant growth due to increasing healthcare investments, a rising patient population, and greater access to new treatments. Emerging markets in Latin America, the Middle East, and Africa are expanding as local healthcare systems develop, more patients gain access to specialized treatments, and the awareness of psoriatic arthritis and its management improves.

Global Psoriatic Arthritis Therapeutics Segment Analysis

In this report, the Global Psoriatic Arthritis Therapeutics Market has been segmented by Drug Class, Route of Administration, Distribution Channel, and Geography.

Global Psoriatic Arthritis Therapeutics Market, Segmentation by Drug Class

The Global Psoriatic Arthritis Therapeutics Market has been segmented by Drug Class into Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Disease-Modifying Antirheumatic Drugs (DMARDs), Immunosuppressants, Biologic Agents, and Others.

NSAIDs are commonly used as the first line of treatment for psoriatic arthritis due to their effectiveness in reducing pain and inflammation. They are widely accessible and provide symptomatic relief, making them a popular choice for managing mild to moderate cases of the disease. However, NSAIDs do not halt disease progression, which limits their long-term use in more severe cases.

DMARDs represent a significant segment of the psoriatic arthritis therapeutics market, offering a more targeted approach by slowing the progression of the disease and preserving joint function. Conventional DMARDs, such as methotrexate, sulfasalazine, and leflunomide, have been the cornerstone of PsA management for many years. These drugs work by modulating the immune system to reduce inflammation and prevent joint damage. In recent years, the introduction of targeted synthetic DMARDs, such as Janus kinase (JAK) inhibitors and phosphodiesterase 4 (PDE4) inhibitors, has expanded the treatment landscape, providing new options for patients who do not respond to traditional therapies.

Biologic agents are among the most advanced and effective treatments for psoriatic arthritis, constituting a substantial portion of the market. These drugs, including tumor necrosis factor (TNF) inhibitors, interleukin (IL)-17 inhibitors, and IL-12/23 inhibitors, target specific components of the immune system involved in the inflammatory process. Biologics have been shown to significantly improve symptoms, inhibit disease progression, and enhance the quality of life for patients with moderate to severe psoriatic arthritis. The high efficacy and specificity of biologics have driven their widespread adoption, despite their higher cost compared to other drug classes. Immunosuppressants and other emerging therapies, including biosimilars and new biologic agents under development, continue to contribute to the diverse and evolving landscape of psoriatic arthritis therapeutics, offering hope for improved outcomes and personalized treatment strategies.

Global Psoriatic Arthritis Therapeutics Market, Segmentation by Route of Administration

The Global Psoriatic Arthritis Therapeutics Market has been segmented by Route of Administration into Oral, Parenteral, and Others.

Oral therapies are a significant segment due to their convenience and ease of use. This category includes traditional DMARDs like methotrexate and newer targeted synthetic DMARDs such as Janus kinase (JAK) inhibitors and phosphodiesterase 4 (PDE4) inhibitors. These oral medications offer the advantage of being easy to administer, which can improve patient adherence and compliance. Their growing popularity is also driven by their effectiveness in managing symptoms and slowing disease progression, making them a viable option for many patients.

Parenteral administration, which includes injectable and intravenous therapies, represents another major segment of the psoriatic arthritis therapeutics market. Biologic agents, a primary treatment option within this category, are typically administered through subcutaneous injections or intravenous infusions. These biologics, including TNF inhibitors, IL-17 inhibitors, and IL-12/23 inhibitors, have demonstrated high efficacy in reducing inflammation and halting disease progression. The precision of these biologic treatments in targeting specific immune system components has made them a cornerstone for managing moderate to severe psoriatic arthritis. Despite the inconvenience of injections and the need for healthcare professional involvement for intravenous infusions, their superior therapeutic outcomes justify their widespread use.

Routes of administration, though less common, also play a role in the treatment of psoriatic arthritis. This category includes topical treatments and transdermal systems primarily used to manage skin symptoms associated with psoriasis. Topical treatments, such as corticosteroids and vitamin D analogs, are applied directly to the skin to reduce local inflammation and alleviate psoriatic plaques. While these treatments do not address joint inflammation, they are often used in conjunction with systemic therapies to provide comprehensive disease management. Additionally, ongoing research and development are exploring novel delivery methods, such as intra-articular injections and advanced drug delivery systems, aiming to improve the efficacy, safety, and patient experience in psoriatic arthritis treatment.

Global Psoriatic Arthritis Therapeutics Market, Segmentation by Distribution Channel

The Global Psoriatic Arthritis Therapeutics Market has been segmented by Distribution Channel into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies.

Hospital pharmacies are a critical distribution channel, serving as the primary source for patients within healthcare facilities. They ensure that patients receive the necessary medications as part of their treatment plans, often working closely with medical staff to provide tailored pharmaceutical care. Hospital pharmacies are equipped to handle specialized and high-cost drugs that may require precise administration and patient monitoring. This channel plays an essential role in the healthcare system by maintaining the continuity of care during a patient's stay, contributing to effective treatment outcomes.

Retail pharmacies are widespread and provide accessible medication solutions to the general public. Located in neighborhoods, shopping centers, and urban areas, retail pharmacies serve as a convenient option for individuals seeking prescription medications, over-the-counter drugs, and general wellness products. They are a primary distribution channel for patients who have been prescribed medications by their doctors and need to fill prescriptions for ongoing treatment. With the growing focus on patient convenience, many retail pharmacies have expanded their services to include home delivery, online ordering, and health consultations, enhancing their role in the healthcare ecosystem.

Online pharmacies have emerged as a significant distribution channel, offering a convenient and efficient way for patients to access medications. With the rise of e-commerce and digital health solutions, online pharmacies allow patients to order prescription and over-the-counter medications from the comfort of their homes. This channel has gained traction due to its convenience, the ability to compare prices, and the ease of accessing medications for those who may have difficulty visiting physical stores. Additionally, online pharmacies have adapted to meet regulatory standards to ensure patient safety and medication authenticity, contributing to their growing popularity.

Global Psoriatic Arthritis Therapeutics Market, Segmentation by Geography

In this report, the Global Psoriatic Arthritis Therapeutics Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Global Psoriatic Arthritis Therapeutics Market Share (%), by Geographical Region, 2024

North America, which holds the largest market share at approximately 40%. This dominance is attributed to several factors, including a well-established healthcare infrastructure, high healthcare expenditure, and significant investment in research and development of new therapies. The United States, in particular, is a major contributor to this market share, with a large patient population, advanced diagnostic capabilities, and a strong presence of leading pharmaceutical companies. Additionally, the availability and adoption of advanced biologic and small molecule therapies are more prevalent in this region compared to others.

Europe holds the second-largest market share, accounting for about 30% of the global psoriatic arthritis therapeutics market. The region's robust healthcare systems, combined with substantial funding for chronic disease management and research, drive this significant share. Key countries such as Germany, the United Kingdom, and France are at the forefront, benefiting from high levels of patient awareness and access to cutting-edge treatments. Moreover, the presence of numerous biopharmaceutical companies and collaborations between academic institutions and industry players further enhance the market's growth in Europe. The implementation of favorable reimbursement policies and increasing focus on personalized medicine also contribute to the region's strong market position.

The Asia-Pacific region is rapidly emerging as a key player in the global psoriatic arthritis therapeutics market, currently holding around 20% of the market share. This growth is fueled by improving healthcare infrastructure, rising prevalence of psoriatic arthritis, and increasing patient awareness about available treatments. Countries such as China, Japan, and India are leading this growth due to their large populations and expanding middle-class segments with greater access to healthcare services. Government initiatives to improve healthcare access and the increasing presence of global pharmaceutical companies in the region are also driving market expansion. The remaining market share is distributed among Latin America and the Middle East and Africa, which are gradually growing due to improvements in healthcare infrastructure and increased adoption of advanced therapeutics.

This report provides an in depth analysis of various factors that impact the dynamics of Global Psoriatic Arthritis Therapeutics Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers, Restraints and Opportunity Analysis

Drivers

• Advancements in Treatment Options
• Rising Awareness and Diagnosis Rates
• Growing Adoption of Biologics

• Improved Healthcare Infrastructure - Improved healthcare infrastructure plays a pivotal role in enhancing the accessibility and quality of treatment for psoriatic arthritis (PsA) patients. Modern healthcare facilities equipped with advanced diagnostic tools and treatment options enable early and accurate detection of PsA, which is crucial for effective management of the condition. With state-of-the-art technology and specialized healthcare professionals, patients can receive tailored treatments that significantly improve their quality of life. Moreover, the expansion of healthcare services into rural and underserved areas ensures that more individuals have access to necessary care, reducing the overall burden of the disease.

  The development of robust healthcare infrastructure also facilitates significant advancements in research and development (R&D) for psoriatic arthritis therapeutics. Hospitals and research centers with cutting-edge technology and equipment can conduct more comprehensive and in-depth studies, leading to the discovery of innovative treatments and therapies. This enhanced R&D capability not only helps in understanding the disease better but also accelerates the process of bringing new drugs and treatment methods to the market. Collaborative efforts between healthcare institutions and pharmaceutical companies can thrive in such environments, fostering innovation and improving treatment outcomes.

  An improved healthcare infrastructure supports extensive patient education and awareness programs, which are essential for the effective management of psoriatic arthritis. Through well-structured educational initiatives, patients can learn about the importance of early diagnosis, adherence to treatment plans, and lifestyle modifications that can help manage their symptoms. Healthcare facilities can provide resources such as support groups, counseling services, and informational workshops, empowering patients to take an active role in their health. Increased awareness and education contribute to better disease management, potentially reducing the incidence of severe complications and improving overall patient outcomes.

Restraints

• Side Effects Associated with Therapies
• Stringent Regulatory Policies
• Lack of Access in Developing Regions

• Limited Patient Awareness in Certain Areas - Limited patient awareness in certain areas significantly hampers the effective management of psoriatic arthritis (PsA). In regions where education about the disease is sparse, many individuals may not recognize the symptoms of PsA or understand the importance of seeking timely medical intervention. This lack of awareness can lead to delayed diagnoses, resulting in the progression of the disease to more severe stages before treatment begins. Consequently, patients may suffer from increased pain, joint damage, and a reduced quality of life, emphasizing the need for targeted awareness campaigns.

  Disseminating information about psoriatic arthritis in underserved areas presents several challenges. These regions may lack the necessary infrastructure, such as reliable healthcare facilities and trained medical personnel, to provide accurate information and support to patients. Additionally, cultural barriers and low literacy rates can further impede the spread of knowledge about PsA. Without effective communication channels and educational resources, residents in these areas remain uninformed about the disease, its symptoms, and available treatments. Addressing these challenges requires innovative strategies and collaboration between healthcare providers, community leaders, and organizations dedicated to health education.

  Improving patient awareness in these areas necessitates a multifaceted approach. Initiatives such as mobile health clinics, community health workshops, and the use of digital platforms can help bridge the information gap. Training local healthcare workers to recognize and educate patients about psoriatic arthritis is also crucial. Partnerships with non-governmental organizations (NGOs) and local governments can enhance the reach and effectiveness of awareness campaigns. Additionally, leveraging social media and other digital tools can disseminate information widely and engage a broader audience. By implementing these strategies, it is possible to increase awareness, promote early diagnosis, and improve the overall management of psoriatic arthritis in underserved regions.

Opportunities

• Innovative Drug Development
• Collaborations and Partnerships Among Key Players
• Increasing Research Funding

• Personalized Medicine Approaches - Personalized medicine approaches in psoriatic arthritis (PsA) therapeutics focus on tailoring treatments to individual patients based on their unique genetic, environmental, and lifestyle factors. This method stands in contrast to the traditional one-size-fits-all approach, offering the potential for more effective and efficient management of PsA. By analyzing a patient's specific genetic markers and immune system characteristics, healthcare providers can identify which treatments are likely to be the most beneficial. This leads to optimized therapeutic strategies that not only improve patient outcomes but also minimize side effects and enhance overall quality of life.

  The advancement of genomic and biomarker research is central to the development of personalized medicine for psoriatic arthritis. Researchers are increasingly able to identify specific genes and biomarkers associated with the disease, which helps in understanding its pathogenesis and progression. This knowledge enables the development of targeted therapies that address the underlying causes of PsA rather than just alleviating symptoms. For instance, biologic drugs tailored to an individual's specific genetic profile can provide more effective disease control. As our understanding of the genetic basis of PsA improves, so does the potential for creating highly personalized and effective treatment regimens.

  While the benefits of personalized medicine approaches in PsA are substantial, including improved patient outcomes and reduced healthcare costs, there are also significant challenges to their widespread implementation. One major hurdle is the high cost associated with genetic testing and the development of targeted therapies. Additionally, there is a need for extensive research and clinical trials to validate the effectiveness of these personalized treatments. Integrating personalized medicine into everyday clinical practice requires substantial investment in healthcare infrastructure, training for healthcare professionals, and patient education. Despite these challenges, the shift towards personalized medicine represents a promising future for PsA therapeutics, with the potential to transform patient care and outcomes significantly.

Key players in Global Psoriatic Arthritis Therapeutics Market include :

• Pfizer
• Eisai
• UCB Biosciences
• Sanofi S.A
• Otsuka Pharmaceutical
• Sumitomo Dainippon Pharma
• Johnson & Johnson
• Celgene Corporation

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis